Fig. 1 | Scientific Reports

Fig. 1

From: ADCY4 inhibits cAMP-induced growth of breast cancer by inactivating FAK/AKT and ERK signaling but is frequently silenced by DNA methylation

Fig. 1

ADCY4 is downregulated in BC and associated with poor prognosis. (A) ADCY4 mRNA expression in primary BC (n = 20) and paired adjacent noncancer tissues (n = 20) by qRT-PCR with β-actin as a control (p = 0.0237, < 0.05). (B) ADCY4 mRNA expression in normal tissues and BC from TCGA datasets using R 3.6.3. package (p = 7.262E-52, < 0.001). (C) ADCY4 mRNA expression in normal tissues (n = 92), adjacent noncancer (n = 104), and BC (n = 1034) from GTEx and TCGA datasets (p < 0.001). (D) The OS rate in the group of high and low ADCY4 expression from TCGA datasets (p = 0.0056, < 0.01). Cutoff value: the median expression level. (E) The difference of OS rate for BC in high and low ADCY4 based on GSE1456 (p = 0.021569, < 0.05). (F) The difference of OS rate for BC in high and low ADCY4 based on GSE3494 (p = 0.017310, < 0.05). (G) Representative IHC staining images of ADCY4 protein expression in adjacent normal breast and BC tissues. The IHC score of ADCY4 in 10 BC specimens (IHC score: 3.10 ± 0.88) was lower than paired 10 adjacent normal breast samples (IHC score: 10.50 ± 2.12) (Mean ± S.D). NC, adjacent normal breast tissues; BrCa, BC tissues. ***p < 0.001.

Back to article page